Monday, October 3, 2022


Biotechnology News Magazine

Karen L Ling Joins Galderma’s Advisory Committee

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Karen L Ling will join the Galderma Advisory Committee, effective March 1, 2022.

Karen L Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wyeth, guiding compensation, culture and program strategies that greatly improved shareholder relations and attracted and retained competitive talent. She is an accomplished global human resources executive with more than 25 years of pharmaceutical industry experience.

Ms. Ling recently retired from her role as Executive Vice President and Chief Human Resources Officer of American International Group, Inc. (AIG). In this role, she oversaw all aspects of human capital management, including talent development, talent acquisition, compensation and benefits, and diversity, equity and inclusion. At Allergan, as Executive Vice President and Chief Human Resources Officer, she unified multiple, successive acquisitions. She was also instrumental in various innovative compensation programs for the executive leadership team, focused on increasing shareholder value.

Thomas Ebeling, Chairman Advisory Committee, Galderma said, “I am very pleased to welcome Ms. Ling to Galderma. She brings to Galderma’s Advisory Committee her extensive expertise in the area of human resources management, having
led the human capital function at major multinational companies. She also has wide experience in mergers and acquisitions – leading seamless integrations and unifying
multiple acquisitions under a shared mission and brand.”

Karen L Ling currently sits on the Board of Directors and Compensation Committee of iRhythm Technologies (NASDAQ: IRTC) and also sits on the Board of Directors and is Chair of the Compensation Committee of TherapeuticsMD (NASDAQ: TXMD). In addition, she sits on the Board of two non-profit organizations, ExpandED and the JED Foundation. Ms. Ling holds a Juris Doctor from the Boston University School of Law and earned her undergraduate degree from Yale University.

“We are thrilled that Karen Ling has decided to join us. Karen has been a strategic advisor to several Boards of Directors and has been a member of the executive leadership teams of a number of global corporations. Karen also has great experience in building strong performance-based and inclusive organizational cultures. This appointment will certainly strengthen our Advisory Committee and also shows our commitment to diversity at
Galderma, ” added Flemming Ørnskov, MD, MPH, CEO of Galderma.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine